Osteosarcoma

Journal of the American Academy of Orthopaedic Surgeons

Volumn 17, Issue 8, 2009, Pages 515-527

  Messerschmitt, Patrick J ^a   Garcia, Ryan M ^a   Abdul Karim, Fadi W ^a   Greenfield, Edward M ^a   Getty, Patrick J ^b,c  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Ireland Cancer Center   (United States)

^c LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 69749101514     PISSN: 1067151X     EISSN: None     Source Type: Journal    
DOI: 10.5435/00124635-200908000-00005     Document Type: Review

References (63)

1. Horner MJ, Ries LAG, Krapcho M, et al: SEER Cancer Statistics Review, 1975-2006. Bethesda, MD, National Cancer Institute. Available at: http://seer.cancer.gov/csr/1975-2006. Accessed May 15, 2009.
2. Hayden JB, Hoang BH: Osteosarcoma: Basic science and clinical implications. Orthop Clin North Am 2006;37:1-7.
3. Carrie D, Bielack SS: Current strategies of chemotherapy in osteosarcoma. Int Orthop 2006;30:445-451.
4. Bielack SS, Kempf-Bielack B, Delling G, et al: Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002;20:776-790.
5. Wang LL: Biology of osteogenic sarcoma. Cancer J2005;11:294-305.
6. Fletcher CD, Unni KK, Mertens F, eds: World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon, France, IARC Press, 2002, pp 227-232, 264-285.
7. Meyers PA, Gorlick R: Osteosarcoma. Pediatr Clin North Am 1997;44:973-989.
8. Scully SP, Ghert MA, Zurakowski D, Thompson RC, Gebhardt MC: Pathologic fracture in osteosarcoma: Prognostic importance and treatment implications. J Bone Joint Surg Am 002;84:49-57.
9. Klein MJ, Siegal GP: Osteosarcoma: Anatomic and histologic variants. Am J Clin Pathol 2006;125:555-581.
10. Mervak TR, Unni KK, Pritchard DJ, McLeod RA: Telangiectatic osteosarcoma. Clin Orthop Relat Res 1991;270:135-139.
11. Murphey MD, wan Jaovisidha S, Temple HT, Gannon FH, Jelinek JS, Malawer MM: Telangiectatic osteosarcoma: Radiologic-pathologic comparison. Radiology 2003;229:545-553.
12. Andresen KJ, Sundaram M, Unni KK, Sim FH: Imaging features of low-grade central osteosarcoma of the long bones and pelvis. Skeletal Radiol 2004;33:373-379.
13. Nakajima H, Sim FH, Bond JR, Unni KK: Small cell osteosarcoma of bone: Review of 72 cases. Cancer 1997;79:2095-2106.
14. Temple HT, Scully SP, O'Keefe RJ, Katapurum S, Mankin HJ: Clinical outcome of 38 patients with juxtacortical osteosarcoma. Clin Orthop Relat Res 2000;373:208-217.
15. Okada K, Frassica FJ, Sim FH, Beabout JW, Bond JR, Unni KK: Parosteal osteosarcoma: A clinicopathological study. JBone Joint Surg Am 1994;76:366-378.
16. Rose PS, Dickey ID, Wenger DE, Unni KK, Sim FH: Periosteal osteosarcoma: Long-term outcome and risk of late recurrence. Clin Orthop Relat Res 2006; 453:314-317.
17. Ritts GD, Pritchard DJ, Unni KK, Beabout JW, Eckardt JJ: Periosteal osteosarcoma. Clin Orthop Relat Res 1987;219:299-307.
18. Grimer RJ, Bielack S, Flege S, et al: Periosteal osteosarcoma: A European review of outcome. Eur J Cancer 2005; 41:2806-2811.
19. Okada K, Unni KK, Swee RG, Sim FH: High grade surface osteosarcoma: A clinicopathologic study of 46 cases. Cancer 1999;85:1044-1054.
20. Link MP, Goorin AM, Horowitz M, et al: Adjuvant chemotherapy of highgrade osteosarcoma of the extremity: Updated results of the Multi-Institutional Osteosarcoma Study. Clin Orthop Relat Res 1991;270:8-14.
21. Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P: Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer 2006;106:1154-1161. (Pubitemid 43297356)
22. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Bone Cancer. National Comprehensive Cancer Network, 2009, version 1, p 14. Fort Washington, PA, National Comprehensive Cancer Network. Available at: http://www.nccn.org/professionals/physician-gls/PDF/bone.pdf. Accessed May 15, 2009.
23. Longhi A, Errani C, De Paolis M, Mercuri M, Bacci G: Primary bone osteosarcoma in the pediatric age: State of the art. Cancer Treat Rev 2006;32:423-436.
24. Enneking WF, Spanier SS, Goodman MA: A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res 1980;153:106-120.
25. Meyers PA, Schwartz CL, Krailo M, et al: Osteosarcoma: A randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 2005;23:2004-2011.
26. Meyers PA, Schwartz CL, Krailo M, et al: Osteosarcoma: The addition of muramyl tripeptide to chemotherapy improves overall survival: A report from the Children's Oncology Group. J Clin Oncol 2008;26:633-638.
27. Kager L, Zoubek A, Potschger U, et al: Primary metastatic osteosarcoma: Presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 2003;21:2011-2018.
28. Kager L, Zoubek A, Kastner U, et al: Skip metastases in osteosarcoma: Experience of the Cooperative Osteosarcoma Study Group. J Clin Oncol 2006;24:1535-1541.
29. Ferrari S, Smeland S, Mercuri M, et al: Neoadjuvant chemotherapy with highdose ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: A joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol 2005;23:8845-8852.
30. Revell MP, Deshmukh N, Grimer RJ, Carter SR, Tillman RM: Periosteal osteosarcoma: A review of 17 cases with mean follow-up of 52 months. Sarcoma 2002;6:123-130.
31. Grimer RJ: Surgical options for children with osteosarcoma. Lancet Oncol 2005; 6:85-92.
32. Smith J, Heelan RT, Huvos AG, et al: Radiographic changes in primary osteogenic sarcoma following intensive chemotherapy: Radiological-pathological correlation in 63 patients. Radiology 1982;143:355-360.
33. Hosalkar HS, Dormans JP: Limb sparing surgery for pediatric musculoskeletal tumors. Pediatr Blood Cancer 2004;42:295-310.
34. Bacci G, Ferrari S, Bertoni F, et al: Histologic response of high-grade nonmetastatic osteosarcoma of the extremity to chemotherapy. Clin Orthop Relat Res 2001;386:186-196.
35. National Cancer Institute: Clinical trials. Bethesda, MD, National Cancer Institute, 2009. Available at: http-//www.cancer.gov/clinicaltrials. Accessed May 15, 2009.
36. Meyers PA, Heller G, Healey J, et al: Chemotherapy for nonmetastatic osteogenic sarcoma: The Memorial Sloan-Kettering experience. J Clin Oncol 1992;10:5-15.
37. Smeland S, Müller C, Alvegard TA, et al: Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: Prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur J Cancer 2003;39:488-494. (Pubitemid 36173693)
38. Harris MB, Gieser P, Goorin AM, et al: Treatment of metastatic osteosarcoma at diagnosis: A Pediatric Oncology Group Study.J Clin Oncol 1998;16:3641-3648.
39. Rougraff BT, Simon MA, Kneisl JS, Greenberg DB, Mankin HJ: Limb salvage compared with amputation for osteosarcoma of the distal end of the femur: A long-term oncological, functional, and quality-of-life study. J Bone Joint Surg Am 1994;76:649-656.
40. Bacci G, Ferrari S, Lari S, et al: Osteosarcoma of the limb: Amputation or limb salvage in patients treated by neoadjuvant chemotherapy. J Bone Joint Surg Br 2002;84:88-92.
41. Simon MA, Aschliman MA, Thomas N, Mankin HJ: Limb-salvage treatment versus amputation for osteosarcoma of the distal end of the femur. J Bone Joint Surg Am 1986;68:1331-1337.
42. Jeys LM, Kulkarni A, Grimer RJ, Carter SR, Tillman RM, Abudu A: Endoprosthetic reconstruction for the treatment of musculoskeletal tumors of the appendicular skeleton and pelvis. J Bone Joint Surg Am 2008;90:1265-1271.
43. Sorger JI, Hornicek FJ, Zavatta M, et al: Allograft fractures revisited. Clin Orthop Relat Res 2001;382:66-74.
44. Mankin HJ, Springfield DS, Gebhardt MC, Tomford WW: Current status of allografting for bone tumors. Orthopedics 1992;15:1147-1154.
45. Nichter LS, Menendez LR: Reconstructive considerations for limb salvage surgery. Orthop Clin North Am 1993;24:511-521.
46. Fuchs B, Kotajarvi BR, Kaufman KR, Sim FH: Functional outcome of patients with rotationplasty about the knee. Clin Orthop Relat Res 2003;415:52-58.
47. Jeys LM, Grimer RJ, Carter SR, Tillman RM: Periprosthetic infection in patients treated for an orthopaedic oncological condition. J Bone Joint Surg Am 2005; 87:842-849.
48. Hazan EJ, Hornicek FJ, Tomford W, Gebhardt MC, Mankin HJ: The effect of adjuvant chemotherapy on osteoarticular allografts. Clin Orthop Relat Res 2001; 385:176-181.
49. Gaffney R, Unni KK, Sim FH, Slezak JM, Esther RJ, Bolander ME: Follow-up study of long-term survivors of osteosarcoma in the prechemotherapy era. Hum Pathol 2006;37:1009-1014.
50. Dahlin DC, Coventry MB: Osteogenic sarcoma: A study of six hundred cases. J Bone Joint Surg Am 1967;49:101-110.
51. Bacci G, Ferrari S, Bertoni F, et al: Longterm outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: An updated report. J Clin Oncol 2000;18:4016-4027.
52. Bacci G, Rocca M, Salone M, et al: High grade osteosarcoma of the extremities with lung metastases at presentation: Treatment with neoadjuvant chemotherapy and simultaneous resection of primary and metastatic lesions. J Surg Oncol 2008;98:415-420.
53. Provisor AJ, Ettinger LJ, Nachman JB, et al: Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: A report from the Children's Cancer Group. J Clin Oncol 1997;15:76-84.
54. Meyers PA, Heller G, Healy JH, et al: Osteogenic sarcoma with clinically detectable metastasis at initial presentation. ; Clin Oncol 1993;11:449-453.
55. Huvos AG: Bone Tumors: Diagnosis, Treatment, and Prognosis, ed 2. Philadelphia, PA, WB Saunders, 1991, pp 122-128.
56. Bacci G, Bertoni F, Longhi A, et al: Neoadjuvant chemotherapy for highgrade central osteosarcoma of the extremity: Histologic response to preoperative chemotherapy correlates with histologic subtype of the tumor. Cancer 2003;97:3068-3075. (Pubitemid 36676262)
57. Kempf-Bielack B, Bielack SS, Jurgens H, et al: Osteosarcoma relapse after combined modality therapy: An analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 2005;23:559-568.
58. Ferrari S, Briccoli A, Mercuri M, et al: Postrelapse survival in osteosarcoma of the extremities: Prognostic factors for long-term survival. J Clin Oncol 2003; 21:710-715.
59. Hawkins DS, Arndt CA: Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy. Cancer 2003;98:2447-2456.
60. Hughes DP, Thomas DG, Giordano TJ, McDonagh KT, Baker LH: Essential erbB family phosphorylation in osteosarcoma as a target for CI-1033 inhibition. Pediatr Blood Cancer 2006; 46:614-623.
61. Messerschmitt PJ, Rettew AN, Brookover RE, Garcia RM, Getty PJ, Greenfield EM: Specific tyrosine kinase inhibitors regulate human osteosarcoma cells in vitro. Clin Orthop Relat Res 2008;466:2168-2175.
62. Bacci G, Ferrari S, Tienghi A, et al: A comparison of methods of loco-regional chemotherapy combined with systemic chemotherapy as neo-adjuvant treatment of osteosarcoma of the extremity. Eur J Surg Oncol 2001;27:98-104.
63. Wilkins RM, Cullen JW, Camozzi AB, Jamroz BA, Odom L: Improved survival in primary nonmetastatic pediatric osteosarcoma of the extremity. Clin Orthop Relat Res 2005;438:128-136.